Skip to content
  • Partnerships
  • News
  • Contact
Fore Biotherapeutics
  • Pipeline
  • Science
    • Plixorafenib Program
    • Publications
  • Patients
    • Our Science Explained
    • Clinical Trials
    • Forte Trial
    • Expanded Access
  • Company
    • About Us
    • People
    • Leadership
    • Investors
    • Careers
    • Governance
Search
  • Pipeline
  • Science
    • Plixorafenib Program
    • Publications
  • Patients
    • Our Science Explained
    • Clinical Trials
    • Forte Trial
    • Expanded Access
  • Company
    • About Us
    • People
    • Leadership
    • Investors
    • Careers
    • Governance
  • Partnerships
  • News
  • Contact

CRISPR-Directed In Vitro Gene Editing of Plasmid DNA Catalyzed by Cpf1 (Cas12a) Nuclease and a Mammalian Cell-Free Extract


April 1, 2018 1:06 PM EDT

Read More

Press Release Jul 20 2017 New partnership between Christiana Care’s Gene Editing Institute and NovellusDx speeds progress toward personalized cancer medicine Read more
Press Release May 22 2017 NovellusDx Registers Another Patent on their FACT™ system,Publishes a New Study With Guardent Health and MD Anderson InCancer Discovery; Was Selected To Present At BioMed, BIO 2017 andASCO Read more
Fore Biotherapeutics logo
  • Science
    • Plixorafenib Program
  • Patients
    • Our Science Explained
    • Clinical Trials
    • Expanded Access
  • Company
    • About Us
    • People
    • Leadership
    • Investors
    • Careers
    • Governance
  • Pipeline
  • Partnerships
  • News
  • Contact
  • Visit us on Twitter
  • Visit us on Linked In
©2025 Fore Biotherapeutics US Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy